6533b7d3fe1ef96bd12615b5
RESEARCH PRODUCT
LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.
S. Di GiacomoB. MatzarellaA. NotarbartoloA. NigriAndrea BerniA. VivenzioStefano BertoliniGiovanna BoscoClaudia StefanuttiV. Colloridisubject
Homozygous Familial Hypercholesterolemiamedicine.medical_specialtyApolipoprotein BBiomedical EngineeringMedicine (miscellaneous)BioengineeringCoronary Disease4.5 years-old girlFamilial hypercholesterolemiaBiomaterialsHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineCoronary Heart DiseaseHumansHyperlipoproteinemia Type IIbiologybusiness.industryCholesterolHomozygoteGeneral MedicineLipoprotein(a)Low Density Lipoprotein (LDL) apheresis; 4.5 years-old girl; Homozygous Familial Hypercholesterolemia; Coronary Heart Diseasemedicine.diseaseLipoproteins LDLApheresisEndocrinologyCholesterolLow Density Lipoprotein (LDL) apheresischemistryLDL apheresisChild Preschoolbiology.proteinBlood Component Removallipids (amino acids peptides and proteins)FemalebusinessLipoproteinLipoprotein(a)description
Preliminary experience with the efficacy and safety of dextran sulfate cellulose low-density lipoprotein (LDL) apheresis for the treatment of a 4.5-year-old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1-68.7%, and 52.5-58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long-term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorporeal treatment with LDL apheresis in children severely affected by homozygous or double heterozygous familial hypercholesterolemia.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1997-10-23 | Artificial organs |